Blueprint Medicines Corp. (NASDAQ:BPMC)’s share price rose 2% during mid-day trading on Thursday . The company traded as high as $28.02 and last traded at $27.75, with a volume of 66,613 shares. The stock had previously closed at $27.21.

BPMC has been the subject of a number of research reports. Cowen and Company reiterated a “buy” rating on shares of Blueprint Medicines Corp. in a report on Tuesday, May 10th. Canaccord Genuity initiated coverage on Blueprint Medicines Corp. in a report on Friday, August 5th. They issued a “buy” rating and a $26.00 price objective for the company. Zacks Investment Research cut Blueprint Medicines Corp. from a “buy” rating to a “hold” rating in a report on Thursday, August 18th. Raymond James Financial Inc. initiated coverage on Blueprint Medicines Corp. in a report on Friday, May 27th. They issued an “outperform” rating and a $23.00 price objective for the company. Finally, TheStreet upgraded Blueprint Medicines Corp. from a “sell” rating to a “hold” rating in a report on Friday, July 29th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Blueprint Medicines Corp. presently has a consensus rating of “Buy” and an average price target of $29.43.

The firm’s market capitalization is $761.27 million. The company’s 50-day moving average price is $23.23 and its 200-day moving average price is $19.24.

Blueprint Medicines Corp. (NASDAQ:BPMC) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.70) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.73) by $0.03. The business had revenue of $7.07 million for the quarter, compared to the consensus estimate of $4.41 million. During the same period in the prior year, the business earned ($0.81) earnings per share. Blueprint Medicines Corp.’s revenue was up 163.0% compared to the same quarter last year. On average, equities research analysts forecast that Blueprint Medicines Corp. will post ($3.05) earnings per share for the current fiscal year.

In other Blueprint Medicines Corp. news, CEO Jeffrey W. Albers sold 17,000 shares of the firm’s stock in a transaction dated Monday, August 8th. The stock was sold at an average price of $22.86, for a total transaction of $388,620.00. Following the sale, the chief executive officer now directly owns 76,494 shares of the company’s stock, valued at $1,748,652.84. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

An institutional investor recently raised its position in Blueprint Medicines Corp. stock. RS Investment Management Co. LLC raised its position in shares of Blueprint Medicines Corp. (NASDAQ:BPMC) by 17.4% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 740,310 shares of the company’s stock after buying an additional 109,878 shares during the period. RS Investment Management Co. LLC owned 2.73% of Blueprint Medicines Corp. worth $19,500,000 as of its most recent SEC filing.

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.